CagriSema versus tirzepatide
CagriSema combines cagrilintide and semaglutide. In REIMAGINE 5, Novo reported greater weight reduction than tirzepatide 5 mg in adults with type 2 diabetes. That is a finding about the specific comparison tested, not proof that CagriSema outperforms every tirzepatide regimen. 1
Why is CagriSema in the news again?
Novo's November 4 update highlights the trial and describes preparations for a possible US launch in early 2027, subject to regulatory approval. A commercial preparation plan is not itself an approval announcement. 2
For readers following the US programme, two questions need separate answers: what the study found, and whether the exact medicine has received a regulatory decision. A positive result can inform an application without completing that application.
What did REIMAGINE 5 compare?
The ClinicalTrials.gov record identifies a randomized, open-label Phase 3 study with 1,023 actual participants. Adults had type 2 diabetes treated with metformin, an SGLT2 inhibitor or both. The registered primary outcomes are HbA1c change and relative body-weight change at week 60. 3
| Study detail | REIMAGINE 5 |
|---|---|
| Investigational arm | CagriSema 1.0 mg/1.0 mg |
| Active comparator | Tirzepatide 5 mg |
| Population | Adults with type 2 diabetes on the specified background treatment |
| Primary assessment | HbA1c and relative body-weight change at 60 weeks |
What results did the company report?
Novo reported estimated average weight reductions of 12.4% with CagriSema and 9.1% with tirzepatide, using the efficacy estimand. It described HbA1c reductions of 1.71 and 1.67 percentage points, respectively, as meeting non-inferiority. Non-inferiority for one endpoint is different from superiority for another. 1
The same announcement also discusses REDEFINE 9, a separate placebo-controlled obesity trial. Its weight-loss percentage should not be placed into the REIMAGINE 5 comparison: the participants, comparator and follow-up question differ. 1
What would a broader comparison need?
To compare other regimens, a reader would need evidence that actually evaluates those regimens in an appropriate population. The result here does not answer a different-dose, different-population or different-duration question simply because the brand names remain similar.
A useful comparison also includes adverse events, discontinuations and the statistical analysis assumptions. The accessible source here is a sponsor topline summary, so it should not be treated as a complete, independently reproduced review of every outcome.
Is CagriSema FDA approved?
The cited announcements describe CagriSema as investigational and its US launch as conditional. The company's filing and anticipated decision window should be distinguished from an actual FDA approval record. 1 2
The next meaningful update would be a dated regulator decision or fuller trial reporting. Keep those developments on this trial-and-status page rather than treating every change in an anticipated launch timetable as a new efficacy result.
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.